Drug Trial Radar · NCT03778073
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Last checked: Nov 20, 2026Latest source record: Aug 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Apr 17, 2019
Primary completion
May 3, 2022
Study completion Aug 1, 2022
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
Conditions
- B-cell Non Hodgkin Lymphoma
- Richter's Transformation
Interventions
CosibelimabDrug
Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
Cosibelimab + Ublituximab + Bendamustine combinationDrug
Cosibelimab (Intravenous infusion): Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles; Ublituximab (Intravenous infusion): Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles; Bendamustine (Intravenous infusion): Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.
Cosibelimab + Ublituximab + Bendamustine combinationDrug
Cosibelimab (Intravenous infusion): Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles; Ublituximab (Intravenous infusion): Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles; Bendamustine (Intravenous infusion): Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events That Are Related to TreatmentTime frame: 6 months of therapy
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
TG Therapeutics Investigational Trial Site
Huntsville, Alabama
TG Therapeutics Investigational Trial Site
Tucson, Arizona
TG Therapeutics Investigational Trial Site
Fayetteville, Arkansas
TG Therapeutics Investigational Trial Site
Peoria, Illinois
TG Therapeutics Investigational Trial Site
Fort Wayne, Indiana
TG Therapeutics Investigational Trial Site
Fairway, Kansas
TG Therapeutics Investigational Trial Site
Louisville, Kentucky
TG Therapeutics Investigational Trial Site
Charlotte, North Carolina
TG Therapeutics Investigational Trial Site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.